- Home
- UFCS vs ORIC Comparison
UFCS vs ORIC Comparison
Compare UFCS & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UFCS | ORIC |
|---|---|---|
| Founded | 1946 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 933.8M | 783.0M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | UFCS | ORIC |
|---|---|---|
| Price | $36.51 | $8.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 12 |
| Target Price | ★ $37.50 | $19.50 |
| AVG Volume (30 Days) | 139.2K | ★ 1.5M |
| Earning Date | 02-10-2026 | 11-13-2025 |
| Dividend Yield | ★ 1.73% | N/A |
| EPS Growth | ★ 118.04 | N/A |
| EPS | ★ 4.24 | N/A |
| Revenue | ★ $1,353,781,000.00 | N/A |
| Revenue This Year | $10.11 | N/A |
| Revenue Next Year | $3.33 | N/A |
| P/E Ratio | $8.73 | ★ N/A |
| Revenue Growth | ★ 12.12 | N/A |
| 52 Week Low | $24.11 | $3.90 |
| 52 Week High | $37.91 | $14.93 |
Technical Indicators
Market Signals| Indicator | UFCS | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 54.15 | 27.86 |
| Support Level | $36.46 | $7.98 |
| Resistance Level | $37.91 | $8.62 |
| Average True Range (ATR) | 0.86 | 0.59 |
| MACD | -0.07 | -0.07 |
| Stochastic Oscillator | 69.49 | 6.71 |
Price Performance
Historical ComparisonAbout UFCS United Fire Group Inc.
United Fire Group Inc is engaged in the business of writing property and casualty insurance and selling annuities through a network of independent agencies. The company's only operating segment is property and casualty insurance, which includes commercial lines insurance, personal lines insurance, and assumed reinsurance. The primary source of revenue is premium and investment income.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.